. 2018 Oct 16;9(21):4000–4008. doi: 10.7150/jca.24250

Table 4.

Univariate and multivariate analysis for OS in matched patients

Variable	group	Univariate analysis				Multivariate analysis
		OS (Months)				Multivariate analysis
		n = 476	Median	95% CI	P	HR	95% CI	P
Sex	Male	438	10.30	9.113 - 11.487
	Female	38	10.30	5.118 - 15.482	0.977
Age (years)	<65	417	9.90	8.904 - 10.896
	>=65	59	14.20	11.934 - 16.466	0.165
Child-Pugh stage	A	444	10.50	9.307 - 11.693
Child-Pugh stage	B	32	7.00	2.605 - 11.395	0.016
ALBI grade	1	193	11.80	10.083 - 13.517
	2	277	9.10	7.792 - 10.408
	3	6	8.80	1.599 - 16.001	0.037
Alpha-Fetoprotein	<= 200	182	12.10	10.149 - 14.051
	200 - 400	19	17.30	1.00 - 35.024
	> 400	275	9.30	8.421 - 10.179	0.027
Tumor number	Unifocal	168	9.80	7.905 - 11.695
Tumor number	Multifocal	308	10.70	9.037 - 12.363	0.622
Portal vein tumor thrombus	Present	319	11.90	10.550 - 13.250
Portal vein tumor thrombus	Absent	157	8.30	7.331 - 9.269	0.002
Albumin, g/L	<35	73	9.30	7.915 - 10.685
	>=35	403	10.50	9.270 - 11.730	0.364
Total bilirubin, μmol/L	>17	314	11.30	10.088 - 12.512
Total bilirubin, μmol/L	<=17	162	9.00	7.946 - 10.054	0.208
Prothrombin time, sec.	>13.5	412	10.30	8.999 - 11.601
Prothrombin time, sec.	<=13.5	64	10.20	5.813 - 14.587	0.755
TACE interval	<=48	238	8.90	7.779 - 10.021
TACE interval	>48	238	12.10	10.445 - 13.755	0.011	1.399	1.135 - 1.725	0.002
Radiologic tumor response	Present	271	13.00	11.438 - 14.562
Radiologic tumor response	Absent	205	8.30	7.370 - 9.230	<0.001	0.636	0.515 - 0.786	< 0.001
Tumor size, cm	<=10	251	12.40	10.714 - 14.086
Tumor size, cm	>10	225	8.90	7.960 - 9.835	0.002	1.366	1.105 - 1.675	0.004

OS: Overall survival; ALBI: Albumin-Bilirubin grade; TACE: transarterial chemoembolization; HR: hazard ratio; CI: Confidence Interval.